SynthesisFrontiers in medicine2021

Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era.

Cori Campbell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.